February 15, 2021
A key health ministry panel will review whether to back approval for JCR Pharmaceuticals’ iduronate-2-sulfatase agent pabinafusp alfa at its meeting on Feb 25, together with other new molecular entities (NMEs). If given the green light by the panel, these...read more